Finasteride sustained release tablets and preparation method thereof

Abstract

The invention discloses finasteride sustained release tablets. The finasteride sustained release tablets are prepared from the following raw materials: 100 to 150 mg of phospholipid, 40 to 70 mg of glyceride, 50 to 60 mg of ethanol, 2 to 5 mg of finasteride, 10 to 50 mg of micropowder silica gel, 20 to 60 mg of chitosan, 20 to 60 mg of an adhesive, 2 to 10 mg of low-substituted hydroxypropyl cellulose, 0.5 to 5 mg of a lubricant and 0.2 to 2 mg of a sweetening agent. The preparation method comprises the following steps: mixing the phospholipid, the glyceride and the finasteride; adding the ethanol and mixing uniformly; adding the micropowder silica gel, the chitosan and the adhesive and mixing uniformly; performing wet granulation; drying; adding the low-substituted hydroxypropyl cellulose, the lubricant and the sweetening agent and mixing uniformly; and tabletting. The finasteride sustained release tablets provided by the invention have a remarkable sustained-release effect, are uniform in release speed and can reduce the use times; the tablets have high uniform strength and good taste; and the tablets can be used for treating male pattern alopecia and benign prostatic hyperplasia.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a finasteride sustained-release tablet and a preparation method thereof. Background technique [0002] Finasteride is a 4-azasteroid that is a specific inhibitor of type II 5α-reductase, an intracellular enzyme involved in the metabolism of testosterone to the stronger dihydrotestosterone. Benign prostatic hyperplasia depends on the conversion of testosterone to dihydrotestosterone in the prostate. Finasteride is very effective in reducing DHT in the blood and in the prostate. Contain type II 5α-reductase in the hair follicle, and the hair follicle becomes less in the bald area scalp of male baldness patient, and dihydrotestosterone increases. Administration of finasteride can reduce the concentration of dihydrotestosterone in the scalp and serum of these patients. Men who are congenitally deficient in type II 5α-reductase do not suffer from male pattern ...

AI Technical Summary

Problems solved by technology

[0005] The disintegration speed of the current conventional finasteride tablet is relatively slow, does not have a sustained release effect, and the bioavailability of the drug is low

Images